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Haploinsufﬁciency of RPS14 in 5q) syndrome is associated with
deregulation of ribosomal- and translation-related genes
The 5q) syndrome is the most distinct of all the myelodys-
plastic syndromes (MDS) (Boultwood et al, 1994a; Giagouni-
dis et al, 2004). Van den Berghe et al (1974) ﬁrst described the
5q) syndrome, noting the consistent association of the loss of
the long arm of chromosome 5 [del(5q)] with the following
haematological features: macrocytosis, anaemia, normal or
high platelet count and hypolobulated megakaryocytes in the
bone marrow. A female preponderance and a good prognosis
have been widely reported in the 5q) syndrome (Boultwood
et al, 1994a; Giagounidis et al, 2004). The 5q) syndrome is
characterised by a clear genotype-phenotype relationship that
is not found in other MDS and acute myeloid leukaemia
(AML) characterised by chromosomal deletions. The
5q) syndrome is recognised as a distinct clinical entity
according to the World Health Organization classiﬁcation
and is deﬁned by a medullary blast count of <5% and the
presence of the del(5q) as the sole karyotypic abnormality
(Vardiman et al, 2002).
The del(5q) in the 5q) syndrome is considered to mark the
location for a gene(s), the loss of which may affect important
processes such as growth control and normal haematopoiesis
(Boultwood et al, 1994a). Our group identiﬁed the commonly
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Summary
We have previously demonstrated haploinsufﬁciency of the ribosomal gene
RPS14, which is required for the maturation of 40S ribosomal subunits and
maps to the commonly deleted region, in the 5q) syndrome. Patients with
Diamond-Blackfan anaemia (DBA) show haploinsufﬁciency of the closely
related ribosomal protein RPS19, and show a consequent downregulation of
multiple ribosomal- and translation-related genes. By analogy with DBA, we
have investigated the expression proﬁles of a large group of ribosomal- and
translation-related genes in the CD34
+ cells of 15 myelodysplastic syndrome
(MDS) patients with 5q) syndrome, 18 MDS patients with refractory
anaemia (RA) and a normal karyotype, and 17 healthy controls. In this
three-way comparison, 55 of 579 ribosomal- and translation-related
probe sets were found to be signiﬁcantly differentially expressed, with
approximately 90% of these showing lower expression levels in the
5q) syndrome patient group. Using hierarchical clustering, patients with
the 5q) syndrome could be separated both from other patients with RA and
healthy controls solely on the basis of the deregulated expression of
ribosomal- and translation-related genes. Patients with the 5q) syndrome
have a defect in the expression of genes involved in ribosome biogenesis and
in the control of translation, suggesting that the 5q) syndrome represents a
disorder of aberrant ribosome biogenesis.
Keywords: 5q) syndrome, RPS14, haploinsufﬁciency, microarray, ribo-
somes.
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5q) syndrome (Boultwood et al, 1994b; Jaju et al, 2000) and
recently narrowed the CDR to the approximately 1Æ5M b
interval at 5q32 ﬂanked by D5S413 and the GLRA1 gene
(Boultwood et al, 2002). A transcription map of the CDR has
been generated (Boultwood et al, 1997, 2000a,b) and the
Ensembl gene prediction program was used for the complete
genomic annotation of this region (Boultwood et al, 2002). We
have shown that the CDR of the 5q) syndrome is gene rich
(Boultwood et al, 2002) and have suggested that one or more
of the 44 candidate genes mapping within this interval
represents the gene or genes critical to the development of
the 5q) syndrome (Boultwood et al, 2002). Several promising
candidate genes have been identiﬁed including the tumour
suppressor gene SPARC, and RPS14, a component of the 40S
ribosomal subunit, and several microRNA genes (Boultwood
et al, 2002, 2007). We performed mutation analysis of all 44
genes mapping to the CDR in a group of patients with the 5q)
syndrome; no mutations were identiﬁed (unpublished data),
supporting the proposal that haploinsufﬁciency (a gene dosage
effect) of one or more of the genes mapping to the CDR is the
pathogenetic basis of the 5q) syndrome.
We have recently demonstrated haploinsufﬁciency of the
ribosomal gene RPS14 in the haematopoietic stem cells (HSC)
in patients with the 5q) syndrome (Boultwood et al, 2007)
and have suggested that it represents a good candidate gene
based on analogy with Diamond-Blackfan anaemia (DBA).
The small-subunit protein Rps14, the yeast homolog of the
bacterial S11 protein, directly binds helix 28 of 18S rRNA and
is essential for the assembly of 40S ribosomal subunits (Larkin
et al, 1987; Moritz et al, 1990). Importantly, haploinsufﬁciency
of a closely related ribosomal protein, RPS19, also required for
the maturation of 40S ribosomal subunits (Flygare et al, 2007),
is one of the causative genes for DBA (Draptchinskaia et al,
1999). DBA is a broad developmental disease characterised by
anaemia, bone marrow erythroblastopenia and an increased
incidence of malignancy (Lipton et al, 2006). Mutations in
RPS19 are found in approximately 25% of DBA patients and
lead to haploinsufﬁciency of RPS19 (Flygare & Karlsson, 2007).
It has recently been suggested that missense mutations in
RPS19 in DBA affect the capacity of the protein to be
incorporated into preribosomes, thus blocking maturation of
the pre40S particles (Gregory et al, 2007). Targeted degrada-
tion of the RPS19 transcript, through retroviral expression of
short hairpin RNAs (shRNAs) has been shown to block the
proliferation and differentiation of erythroid progenitor cells
in cultured human CD34
+ cells (Ebert et al, 2005). Therefore,
deﬁciency of RPS19 blocks proliferation of immature erythroid
progenitor cells. Recently, the identiﬁcation of a second DBA
gene has established DBA as a ribosomal disorder because the
affected gene (RPS24) encodes ribosomal protein S24 (Gazda
et al, 2006a).
The anaemia in DBA and the 5q) syndrome is due to a
failure of erythropoiesis and intriguingly both disorders show
haploinsufﬁciency for ribosomal proteins, RPS19 and RPS14
respectively, required for the maturation of 40S ribosomal
subunits. Most recently, Ebert et al (2008) have shown that the
knock-down of RPS14 in CD34
+ cells using RNAi results in a
block in erythroid differentiation (leading to erythroid cell
apoptosis) with relative preservation of megakaryocyte differ-
entiation, closely mirroring the defects observed in the
5q) syndrome. Moreover, forced expression of an RPS14
cDNA in primary bone marrow cells from patients with the
5q) syndrome rescued the phenotype (Ebert et al, 2008).
RPS14 clearly represents a strong candidate gene for the
5q) syndrome (Boultwood et al, 2007; Ebert et al, 2008).
In RPS19-deﬁcient DBA, the impaired 40S ribosomal
subunit biogenesis suggests impaired translation as the mech-
anism that causes anaemia in DBA (Flygare & Karlsson, 2007).
In accord with this hypothesis, global gene expression proﬁles
in the haematopoietic progenitor cells of patients with DBA
are characterised by downregulation of multiple ribosomal
genes, as well as several genes which are required for
translation initiation and elongation (Gazda et al, 2006b).
Intriguingly, we have previously shown that MDS patients with
the del(5q) show deregulation of genes involved in translation
initiation when compared to MDS without the del(5q)
(Pellagatti et al, 2006). Prompted by these observations,
together with our recent demonstration of haploinsufﬁciency
of RPS14 in the 5q) syndrome, we investigated the expression
levels of ribosomal genes and genes involved in translation
initiation and elongation in the HSC of patients with the
5q) syndrome.
Materials and methods
Sample collection and cell separation
Fifteen patients with MDS 5q) syndrome, 18 MDS patients
with refractory anaemia (RA) and a normal karyotype, and 17
healthy controls were included in the study. Classiﬁcation of
MDS patients was according to the French–American–British
(FAB) criteria (Bennett et al, 1982). Patients with the 5q)
syndrome had a del(5q) as the sole chromosomal abnormality
and characteristic clinical morphological features (Giagounidis
et al, 2004). The MDS patient samples were collected from
several centres: Oxford and Bournemouth (United Kingdom),
Duisburg (Germany), Stockholm (Sweden) and Pavia (Italy).
The study was approved by the ethics committees (Oxford
C00.196, Bournemouth 9991/03/E, Duisburg 2283/03, Stock-
holm 410/03, Pavia 26264/2002) and informed consent was
obtained. Bone marrow samples were obtained and CD34
+
cells isolated from MDS patients and healthy controls.
Mononuclear cells were separated using Histopaque (Sigma-
Aldrich, Gillingham, UK) density gradient centrifugation,
labelled with CD34 MicroBeads, and then CD34
+ cells were
isolated using MACS magnetic cell separation columns (Milt-
enyi Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s recommendations. The purity of CD34
+ cell
preparations was evaluated with FACS and was ‡90%.
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Total RNA was extracted using TRIZOL (Invitrogen, Paisley,
UK) following the manufacturer’s protocol. The quality of the
RNA samples was evaluated using Agilent Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA, USA). For each sample,
50 ng of total RNA were ampliﬁed and labelled with the Two-
Cycle cDNA Synthesis and the Two-Cycle Target Labelling and
Control Reagent packages (Affymetrix, Santa Clara, CA, USA).
10 lg of biotin-labelled fragmented cRNA was hybridised to
GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix),
covering over 47 000 transcripts representing 39 000 human
genes. Hybridisation was performed at 45 C for 16 h in
Hybridization Oven 640 (Affymetrix). Chips were washed and
stained in a Fluidics Station 450 (Affymetrix) and scanned
using a GeneChip Scanner 3000 (Affymetrix).
Microarray data analysis
Cell intensity calculation and scaling was performed using
GeneChip Operating Software (GCOS). Data analysis was
performed using GeneSpring 7.3.1 (Agilent Technologies). The
GCOS software was used to perform quality control after
scaling the signal intensities of all arrays to a target of 100. The
values obtained for scale factors, background levels, percentage
of present calls, 3¢/5¢ GAPDH ratio and intensities of spike
hybridisation controls were within the acceptable range for all
samples. Affymetrix CEL ﬁles were preprocessed using Robust
MultiChip Analysis (RMA) (Irizarry et al, 2003). Hierarchical
clustering was performed with GeneSpring software using
Pearson correlation. The Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID; http://david.abcc.
ncifcrf.gov/) (Dennis et al, 2003) was used to identify enriched
biological themes, in particular gene ontology terms.
Real-time quantitative polymerase chain reaction (PCR)
The expression data for selected genes were validated using
real-time quantitative PCR. The expression level of the beta-
2-microglobulin gene (B2M) was used to normalise for
differences in input cDNA. Predeveloped TaqMan Assays were
used (Assays-on-Demand, Applied Biosystems, Foster City,
CA, USA) and reactions were run on a LightCycler 480 Real-
Time PCR System (Roche Diagnostics, Lewes, UK). Each
sample was performed in triplicate and the expression ratios
were calculated using the DDCT method (Livak & Schmittgen,
2001).
Results
The expression proﬁles of 579 probe sets for ribosomal- and
translation-related genes (obtained from the GeneSpring
software) were evaluated in the CD34
+ cells obtained from
15 MDS patients with 5q) syndrome, 18 MDS patients with
RA and a normal karyotype and 17 healthy controls. Of these
579 probe sets, 229 were for RPL (large subunit ribosomal
protein) genes, 176 for RPS (small subunit ribosomal protein)
genes, 149 for EIF (eukaryotic translation initiation factor)
genes and 25 for EEF (eukaryotic translation elongation
factor) genes. 55 of these 579 ribosomal- and translation-
related probe sets were signiﬁcantly differentially expressed
(analysis of variance [anova] P <0 Æ01, Benjamini-Hochberg
multiple testing correction) in the three-way comparison of
the 5q) syndrome, MDS with RA and a normal karyotype, and
healthy control groups, with four probe sets mapping to
chromosome 5q (Table I). 49 of the 55 (89%) signiﬁcantly
differentially expressed probe sets showed lower expression
levels in the 5q) syndrome patient group. Hierarchical
clustering performed using these 55 probe sets (26 RPL, 15
RPS, 11 EIF, 3 EEF) grouped the patients with 5q) syndrome
together, while no separation was observed between MDS
patients with RA and a normal karyotype and healthy controls
(Fig 1). A two-way scatterplot using the data for two of the
most signiﬁcant genes identiﬁed could effectively separate the
patients with 5q) syndrome from the patients with RA and a
normal karyotype and the healthy controls (Fig 2).
By repeating the three-way comparison using all 54 675
genes on the array, 467 genes were signiﬁcantly differentially
expressed between the three groups (anova P <0 Æ01, Benja-
mini-Hochberg multiple testing correction). The web-accessi-
ble DAVID program was used to identify enriched biological
themes, particularly gene ontology terms, within this gene list
(Table II).
We compared our data with the results reported by Gazda
et al (2006b), describing the defective expression of ribosomal
protein genes in DBA. Three of our 55 signiﬁcantly differen-
tially expressed ribosomal- and translation-related genes
(RPL28, RPS14 and EEF1D) were in common with this paper
(Table I), and similarly we found them downregulated in
patients with the 5q) syndrome. In addition, in the compar-
ison using all genes on the array, two of the 467 signiﬁcantly
differentially expressed genes identiﬁed (TNFRSF10B and
BAX) were common to the results of Gazda et al (2006b),
and similarly we found them upregulated in patients with the
5q) syndrome.
The expression levels of these ﬁve genes (RPS14, EEF1D,
RPL28, TNFRSF10B and BAX), in common with Gazda et al
(2006b), were validated using real-time quantitative PCR
(Fig 3). Real-time quantitative PCR experiments conﬁrmed
the downregulation of RPS14, EEF1D and RPL28 and the
upregulation of TNFRSF10B and BAX in the 5q) syndrome
patients.
Discussion
Much progress has been made regarding the mapping of the
CDR of the 5q) syndrome and the identiﬁcation of candidate
genes (Boultwood et al, 2002). One interesting gene that has
been mapped to the CDR is the ribosomal gene RPS14
(Boultwood et al, 2002), encoding a protein required for the
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Moritz et al, 1990). We have recently demonstrated haploin-
sufﬁciency of the ribosomal gene RPS14 in the HSC of patients
with the 5q) syndrome and have suggested that RPS14
represents a good candidate gene for this disorder (Boultwood
et al, 2007). Recently, Ebert et al (2008) provided compelling
evidence demonstrating that RPS14 is a causal gene for the 5q)
syndrome. The analogy with DBA is very striking in that this
disease is frequently caused by haploinsufﬁciency of another
ribosomal protein, the RPS19 protein, and is characterised by a
failure of erythropoiesis and an increased risk of leukaemic
transformation (Lipton et al, 2006). The hypothesis under
consideration in this study is that DBA and the 5q) syndrome
share a related molecular basis in that they are both disorders
of defective ribosomal biogenesis.
The expression proﬁles of a large group of ribosomal- and
translation-related genes were determined in the CD34
+ cells
of 15 MDS patients with 5q) syndrome, 18 MDS patients with
RA and a normal karyotype, and 17 healthy controls. 55 of
these 579 ribosomal- and translation-related probe sets were
signiﬁcantly differentially expressed in the three-way compar-
ison of the patient/control groups with approximately 90% of
Table I. The signiﬁcant differentially expressed probe sets between MDS patients with 5q) syndrome, MDS patients with RA and a normal
karyotype, and healthy controls. Probe sets are ranked by decreasing P-value after adjustment for multiple testing. Genes in bold are common with
Gazda et al (2006b). The full dataset is available as Supplementary Information (Table SI).
Probe set ID
Gene
symbol Map
Mean ratio
5q) syndrome
Mean ratio
RA normal
karyotype
Mean ratio
healthy
controls
Adjusted
P-value
218007_s_at RPS27L 15q22Æ21 Æ93 1Æ34 0Æ95 3Æ25 · 10
)8
214919_s_at EIF4EBP3 5q31Æ30 Æ53 1Æ17 1Æ01 4Æ00 · 10
)7
208645_s_at RPS14 5q31-q33 0Æ68 0Æ94 0Æ97 6Æ28 · 10
)6
218339_at MRPL22 5q33Æ1-q33Æ30 Æ54 1Æ16 1Æ00 7Æ36 · 10
)6
238026_at RPL35A 3q29-qter 0Æ64 1Æ06 1Æ02 1Æ77 · 10
)5
223015_at EIF2A 3q25Æ10 Æ62 0Æ77 0Æ96 9Æ10 · 10
)5
210501_x_at EIF3K 19q13Æ20 Æ75 1Æ07 1Æ04 1Æ05 · 10
)4
212039_x_at RPL3 22q13 0Æ92 1Æ01 0Æ99 1Æ10 · 10
)4
225541_at RPL22L1 3q26Æ20 Æ64 1Æ09 1Æ02 1Æ77 · 10
)4
213223_at RPL28 19q13Æ40 Æ73 1Æ10 1Æ00 3Æ37 · 10
)4
217719_at EIF3EIP 22q 0Æ83 0Æ98 1Æ01 3Æ85 · 10
)4
227708_at EEF1A1 6q14Æ10 Æ56 0Æ85 0Æ97 5Æ10 · 10
)4
200005_at EIF3D 22q13Æ10 Æ81 1Æ10 1Æ10 5Æ14 · 10
)4
203113_s_at EEF1D 8q24Æ30 Æ72 1Æ12 1Æ05 5Æ75 · 10
)4
214317_x_at RPS9 19q13Æ40 Æ88 1Æ07 1Æ00 1Æ22 · 10
)3
216588_at RPL7 8q21Æ11 0Æ80 0Æ88 0Æ96 1Æ22 · 10
)3
214042_s_at RPL22 1p36Æ3-p36Æ20 Æ79 0Æ88 0Æ98 1Æ64 · 10
)3
221593_s_at RPL31 2q11Æ20 Æ59 1Æ06 0Æ97 1Æ64 · 10
)3
236990_at EIF2AK3 2p12 0Æ68 0Æ82 1Æ07 1Æ77 · 10
)3
224767_at RPL37 5p13 0Æ77 1Æ23 1Æ03 1Æ97 · 10
)3
214097_at RPS21 20q13Æ30 Æ57 0Æ91 0Æ88 1Æ97 · 10
)3
200074_s_at RPL14 3p22-p21Æ20 Æ81 1Æ03 1Æ02 2Æ18 · 10
)3
212578_x_at RPS17 15q 0Æ91 0Æ99 1Æ01 2Æ64 · 10
)3
200819_s_at RPS15 19p13Æ30 Æ92 1Æ03 0Æ99 2Æ64 · 10
)3
214271_x_at RPL12 9q34 0Æ91 1Æ06 0Æ99 4Æ54 · 10
)3
229590_at RPL13 16q24Æ30 Æ73 1Æ22 1Æ05 4Æ54 · 10
)3
238448_at MRPL19 2q11Æ1-q11Æ21 Æ41 1Æ00 1Æ00 5Æ78 · 10
)3
224330_s_at MRPL27 17q21Æ3-q22 1Æ32 1Æ47 1Æ02 5Æ82 · 10
)3
226190_at RPL4 15q22 1Æ54 1Æ13 1Æ02 5Æ86 · 10
)3
208697_s_at EIF3E 8q22-q23 0Æ80 0Æ99 1Æ00 6Æ13 · 10
)3
200715_x_at RPL13A 19q13Æ30 Æ76 1Æ01 0Æ99 6Æ42 · 10
)3
211937_at EIF4B 12q13Æ13 0Æ88 1Æ22 1Æ03 6Æ49 · 10
)3
212537_x_at RPL17 18q21 0Æ87 1Æ03 1Æ00 6Æ49 · 10
)3
227722_at RPS23 5q14Æ20 Æ53 0Æ80 0Æ95 6Æ49 · 10
)3
1556383_at RPS27 1q21 0Æ83 0Æ84 1Æ05 7Æ08 · 10
)3
202029_x_at RPL38 17q23-q25 0Æ91 1Æ07 1Æ00 7Æ54 · 10
)3
200094_s_at EEF2 19pter-q12 0Æ83 1Æ08 1Æ02 7Æ54 · 10
)3
224930_x_at RPL7A 9q34 0Æ89 1Æ01 1Æ04 7Æ61 · 10
)3
A. Pellagatti et al
ª 2008 The Authors
60 Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 142, 57–64the signiﬁcantly differentially expressed genes showing lower
expression levels in the 5q) syndrome patient group. Hierar-
chical clustering performed using these 55 probe sets grouped
the patients with 5q) syndrome together, while no separation
was observed between MDS patients with RA and a normal
karyotype and healthy controls. Thus patients with the 5q)
syndrome can be separated both from other patients with RA
and normal individuals solely on the basis of the deregulated
expression of ribosomal- and translation-related genes.
Of the 55 signiﬁcantly differentially expressed ribosomal-
related probe sets in the HSC of the 5q) syndrome 26
represented RPL and 15 RPS. 35 out of these 41 probe sets
showed downregulation in patients with the 5q) syndrome
compared to healthy controls and patients with RA and a
normal karyotype. Approximately half of these ribosomal
genes showed a reduction in expression levels within the
range 0Æ5–0Æ8 in patients with the 5q) syndrome, including
RPS14, RPS23, RPL28, RPL31 and RPL22L1. The ﬁndings of
Gazda et al (2006b) indicate that some ribosomal protein
genes are closely co-regulated in humans and that haplo-
insufﬁciency for RPS19 results in downregulation of the
additional ribosomal protein genes in both haematopoietic
progenitor and erythroid cells in DBA patients. We suggest
that haploinsufﬁciency for RPS14 in the 5q) syndrome
results in a similar downregulation of a group of ribosomal
genes in the HSC of such patients.
The ratios for two of the most signiﬁcant genes were plotted
in a scatterplot to see if they alone could separate 5q) syndrome
patients from patients with RA and a normal karyotype and
healthy controls. The scatterplot obtained using the genes
RPL35A and RPS14 showed that the 5q) syndrome patients
could be separated from patients with RA and a normal
karyotype and healthy controls. This illustrates the diagnostic
potential of ribosomal gene expression in the 5q) syndrome. It
would be interesting to determine whether this diagnostic
strategy could be transferred to peripheral blood leucocytes.
One ribosomal gene, RPS27L, showed upregulation by
approximately twofold in patients with the 5q) syndrome
compared to healthy controls. It has been recently shown that
RPS27L is a p53-induced gene that promotes apoptosis
(Lindstrom et al, 2007). Interestingly, a high level of apoptosis
is found in patients with early MDS (Tehranchi et al, 2005),
including the 5q) syndrome.
The HSC of patients with the 5q) syndrome also showed
signiﬁcant downregulation of many genes encoding proteins
important for translation including the eukaryotic translation
Fig 1. Hierarchical clustering of 55 differentially expressed genes between MDS patients with 5q) syndrome (red), MDS patients with RA and a
normal karyotype (green), and healthy controls (blue). Each row represents a single Affy probe set and each column a separate CD34+ sample.
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translation elongation factors EEF1D and EEF1A1. The fact that
several signiﬁcantly underexpressed genes encode proteins
involved in translation suggests that this process is dysregulated
in the HSC of patients with the 5q) syndrome. In support of
this ﬁnding, we have previously reported that patients with
MDS with a del(5q) show signiﬁcant deregulation of genes
involved in translational initiation when compared to MDS
patients without the del(5q) (Pellagatti et al, 2006).
The data generated by this study in patients with the 5q)
syndrome was compared with the data concerning deregulated
ribosomal gene expression recently reported in RPS19-deﬁ-
cient DBA by Gazda et al (2006b) and, interestingly, the
ribosomal- and translation-related genes RPL28, RPS14 and
EEF1D were found to be downregulated in both disorders.
Moreover, several pro-apoptotic genes, including TNFRSF10B
and BAX were upregulated in both disorders (Gazda et al,
2006b).
Next, in an analysis of the entire gene expression data sets,
signiﬁcantly deregulated biological processes were investigated
in patients with the 5q) syndrome. The most signiﬁcantly
deregulated gene ontology category in patients with the
5q) syndrome compared to patients with RA and a normal
karyotype and healthy controls was protein biosynthesis, with
protein metabolism and translation also signiﬁcantly deregu-
lated. This data strongly supports the proposal that the HSC of
patients with the 5q) syndrome are characterised by impaired
protein biosynthesis and translation.
We have previously reported that the HSC of MDS patients
with the del(5q), including patients with the 5q) syndrome,
showed upregulation of histone genes and genes related to the
actin cytoskeleton (Pellagatti et al, 2006; Boultwood et al,
2007). We suggest that these ﬁndings may be directly related to
impaired translation in these cells. Intriguingly, superinduc-
tion of histone mRNAs has been reported when protein
translation is inhibited (Sive et al, 1984). Moreover, it has
recently been shown that improper organisation of the actin
cytoskeleton affects protein synthesis at initiation (Gross &
Kinzy, 2007). The eukaryotic translation elongation factor 1A
(EEF1A) and other actin binding proteins are known to affect
translation initiation through the actin cytoskeleton (Gross &
Kinzy, 2007). The present study showed that EEF1A was
downregulated in the HSC of patients with the 5q) syndrome
by approximately 2-fold. Impaired protein translation in the
HSC of patients with the 5q) syndrome may thus be the cause
of the increased histone expression and deregulated actin
cytoskeleton observed in these cells.
One important question is how a defect in ribosomal
biogenesis and translation could lead to the development of a
clonal haematological disorder. DBA is clearly associated with
an increased risk of cancer (Lipton et al, 2006) and, as
proposed for DBA, it may be that in the 5q) syndrome the
secondary reduction of other ribosomal protein genes is a
contributing factor. Indeed, there is increasing evidence that
abnormalities in ribosome gene expression and biogenesis may
play an important role in tumorigenesis. It is now recognised,
for example, that certain ribosomal proteins have extraribos-
omal functions concerning the regulation of p53 and the cell
cycle (Dai & Lu, 2004; Jin et al, 2004). Interestingly, it has
recently been shown that many ribosomal genes are cancer
causing genes in the zebraﬁsh (Amsterdam et al, 2004). In an
investigation of several hundred lines of zebraﬁsh, each
heterozygous for a recessive embryonic lethal mutation, 11
out of 12 lines with an elevated cancer incidence were
heterozygous for a mutation in a different ribosomal protein
gene. These ﬁndings are strong evidence that many ribosomal
protein genes act as haploinsufﬁcient tumour suppressors
(Amsterdam et al, 2004). Intriguingly, several of these genes
were amongst the group of ribosomal genes that were found to
be downregulated in patients with the 5q) syndrome in this
study, including RPL7 and RPL13. Alternatively, it may be that
Fig 2. Scatterplot of the ratios for the genes RPS14 and RPL35A in
patients with the 5q) syndrome, patients with RA and a normal
karyotype, and healthy controls.
Table II. Signiﬁcantly enriched gene ontology terms within the list of
467 signiﬁcantly differentially expressed genes in 5q) syndrome versus
RA with a normal karyotype versus healthy controls.
Gene ontology category
Number
of genes Adj. P-value
Protein biosynthesis 40 2Æ2 · 10
)7
Macromolecule biosynthesis 40 4Æ1 · 10
)6
Biosynthesis 52 1Æ5 · 10
)4
Protein metabolism 96 1Æ9 · 10
)4
Cellular biosynthesis 47 3Æ3 · 10
)4
Cellular macromolecule metabolism 90 3Æ8 · 10
)4
Translation 16 5Æ3 · 10
)4
Cellular protein metabolism 88 5Æ3 · 10
)4
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the 5q) syndrome such as the tumour suppressor gene SPARC
(Boultwood et al, 2007) play an important role in establishing
clonal dominance in the 5q) syndrome.
The present study showed that patients with the 5q)
syndrome have a defect in the expression of genes involved in
ribosome biogenesis and in the control of translation. By
analogy with DBA, we suggest that the deregulation observed
in ribosomal gene expression and translation-related gene
expression in the HSC of patients with the 5q) syndrome are
secondary to RPS14 haploinsufﬁciency. These abnormalities
may lead to impairment of ribosome biogenesis and
subsequent reduction of protein translation capacity. The
5q) syndrome is characterised by a macrocytic anaemia and
this ribosomal abnormality may be particularly crucial for
developing erythroid cells, whose survival and division require
large amounts of protein synthesis. These data support the
hypothesis that the 5q) syndrome represents a disorder of
impaired ribosomal biogenesis.
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